Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
WisdomTree heads into its October 30 earnings date with shorts unwinding, analysts raising targets across the board, and retail attention running well above normal, yet the stock has given back ground all week.
The short interest picture has shifted materially in the right direction for bulls. At 9.6% of free float, the position is still elevated in absolute terms, but it has fallen roughly 5.8% over the past week and around 7.2% over the past month, a steady bleed rather than a dramatic cover. The lending market is relaxed: availability is running at 283%, meaning there are nearly three shares available to borrow for every one already shorted, far above the 52-week tightest reading of 59%. Borrowing costs confirm the loose conditions, with cost to borrow at just 0.53%, up modestly on the week but nowhere near stress territory. Options positioning is barely defensive, with a put/call ratio of 0.023, only slightly above its 20-day average and a tiny fraction of the 52-week high of 0.20. Taken together, the lending and derivatives markets suggest no particular urgency from short sellers, and no squeeze pressure building from the other side.
The Street has been consistently more bullish on valuation in recent months. Every recent analyst action has been a target raise, with no cuts. The most notable came on October 2, when Goldman Sachs lifted its target to $21.30 from $18.30 while keeping a Neutral rating, and Craig-Hallum moved its target to $29 from $24 on a Buy. Morgan Stanley raised to $27 from $21 on September 25, maintaining Equal-Weight. The mean consensus target is $26.33 against a current price of $23.37, implying around 13% upside at current levels, though Goldman's Neutral at $21.30 sits below the stock. The divergence between the more cautious bellwether view and the outright bulls at Craig-Hallum and Oppenheimer captures the central debate: WisdomTree's valuation expansion has been dramatic, and whether the fundamentals can catch up is the live question. The PE multiple is running at about 17.9 times, down modestly over the past month alongside the price. The ORTEX short score has drifted lower all week, from 62.5 to 59.1, consistent with the short interest reduction rather than any fresh build.
One ownership dynamic worth flagging is the ongoing shift in FMR's position. The firm filed a Schedule 13G/A on October 7, its latest disclosure, showing a stake now at 3.2% of the class, down from 9.4% at its prior filing. Current institutional data shows FMR holding just over 13.5 million shares as of September 30, with an addition of around 842,000 shares in that reporting period, so the 13G/A reflects an earlier reduction that has since been partially rebuilt or the filings do not align cleanly with the current snapshot. Separately, Azora Capital's last disclosed position of 4.8% (down from 6.2%) and ETFS Capital's reduction from 6.3% to 3.6% both indicate notable selling at former stakeholders. The caveat applies: Schedule 13D/G positions are event-driven disclosures around the 5% threshold, and holders who drop below 5% may not file again. The founder, Jonathan Steinberg, holds 6.6% with no change at last report.
Insider activity has been quiet in open-market terms. The only recent transaction of substance was a planned sale by President and COO Jarrett in September, 30,000 shares at $24.56 for around $737,000, executed under a 10b5-1 plan. Pre-arranged sales carry less directional weight than discretionary ones, and this follows a similar plan-driven sale in May at $18.99. Net insider activity over 90 days is a modest negative, entirely attributable to those two scheduled sales.
Wikipedia attention is running at a z-score of 2.24 above its own 90-day history as of September 22, according to the ORTEX alt-data signal combining English Wikipedia page views and ORTEX stock page traffic. This is a measure of retail attention rather than a financial indicator, but the elevated reading is notable given the stock is down 6% over the past month. Retail eyeballs on a declining name can cut either way.
With earnings on October 30 and the stock down 3.8% on the week to $23.37, the setup to watch is whether the ongoing short interest reduction continues into the print, and whether the Street's broadly higher targets will attract buyers to fill the gap left by institutional sellers.
See the live data behind this article on ORTEX.
Open WT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
